Smartleaf Asset Management
BCRX icon

Smartleaf Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Smartleaf Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.12K Sell
498
-228
-31% -$2.15K ﹤0.01% 2797
2026
Q2 		$6.93K Hold
726
– – ﹤0.01% 2542
2026
Q1 		$6.86K Sell
726
-229
-24% -$1.78K ﹤0.01% 2503
2025
Q4 		$7.32K Buy
955
+17
+2% +$123 ﹤0.01% 2531
2025
Q3 		$7.08K Buy
938
+647
+222% +$5.39K ﹤0.01% 2249
2025
Q2 		$2.72K Buy
291
+203
+231% +$1.89K ﹤0.01% 2245
2025
Q1 		$691 Sell
88
-452
-84% -$3.65K ﹤0.01% 2642
2024
Q4 		$4.07K Buy
540
+360
+200% +$2.73K ﹤0.01% 2324
2024
Q3 		$1.37K Buy
+180
New +$1.37K ﹤0.01% 2586

Other funds holding BCRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
JHC
Jones Hill Capital New York $589M AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Smartleaf Asset Management's BCRX Position: Q3 2026 in Review

Smartleaf Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 31% in Q3 2026, selling an estimated $2.15K and leaving 498 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2797.

Smartleaf Asset Management first reported a position in BCRX in Q3 2024 and has held it in 9 quarters since. The position peaked at $7.32K in Q4 2025. 241 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Smartleaf Asset Management held 498 shares of BioCryst Pharmaceuticals worth $4.12K as of Q3 2026.
  • Smartleaf Asset Management sold 228 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $2.15K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2797 holding.
  • Smartleaf Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's BioCryst Pharmaceuticals position peaked at $7.32K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.